Angiopoietin-Like Protein 4 and Insulin-Like Growth Factor-1 Expression in Invasive Breast Carcinoma in Young Women

Biomarker identification is imperative for invasive breast carcinoma, which is more aggressive and associated with higher mortality and worse prognosis in younger patients (<45 years) than in older patients (>50 years). The current study aimed to investigate angiopoietin-like protein 4 (ANGPTL4) and insulin-like growth factor-1 (IGF-1) protein expression in breast tissue from young patients with breast carcinoma. Immunohistochemical staining was applied in formalin-fixed, paraffin-embedded samples of breast carcinoma tissue from young patients aged <45 years at the time of diagnosis. Both proteins were expressed in the majority of cases. The highest frequency of positive ANGPTL4 and IGF-1 expression was observed in the luminal A subtype, whereas the HER2-overexpression subtype exhibited the lowest expression frequency for both proteins. There was no significant association between ANGPTL4 (p = 0.897) and IGF-1 (p = 0.091) expression and molecular subtypes of breast carcinoma. The histological grade was a significant predictor of ANGPTL4 expression (grade 1 vs. grade 3, adjusted odds ratio = 12.39, p = 0.040). Therefore, ANGPTL-4 and IGF-1 expressions are common in young breast carcinoma tissue. There is a potential use of them as biomarkers in breast carcinoma.

Methylation level of ASC/TMS1 and MyD88 genes in healthy larynx and laryngeal carcinoma tissue

There are no biomarkers for diagnosis, prognosis and treatment of patients with laryngeal carcinoma. Methylation changes of ASC/TMS1 and MyD88 genes, in healthy and cancer tissue, might be related with development and progression of cancer. The study explored is there a difference in gene’s methylation in healthy and tumor tissue and does it correlate with protein expression. The total of 36 patients were enrolled in the study. Methylation of bisulphite converted DNA was quantified by pyrosequencing in fresh frozen cancer and adjacent non-malignant tissues. The overall methylation of MyD88 gene is significantly higher in healthy tissue and this finding correlates with protein expression and the overall methylation of ASC/TMS1 gene is unchanged but the protein expression of ASC/TMS1 is significantly higher in cancer. The methylation status of the ASC/TMS1 and MyD88 genes are promising prognostic biomarker candidates and may lead to earlier detection of laryngeal cancer.

PTCSC1 Promotes Bladder Cancer Progression by AKT Pathway

In bladder cancer the expression of PTCSC1is elevated, but how PTCSC1influencetumor progression are still unclear. We found that in human bladder cancer PTCSC1 is upregulated. The study showedthat the expression level of PTCSC1 is higher in bladder cancer tissuesthan that of PTCSC1 in para-carcinoma tissue. Furthermore, PTCSC1promoted bladder cancer cell migration and invasion, and decreased expression of PTCSC1 inhibited the expression of matrix metalloprotease MMP2and MMP9, and increased the expression level of E-cadherin. PTCSC1 promoted tumor growth in a mouse model of human bladder cancer. Additionally,PTCSC1 shRNA caused a significant decrease in p-AKTexpression in T24 cells and BIU-87 cells, but the overexpression ofPTCSC1got an opposite result.Allthe results showed that PTCSC1 can influencebladder cancer cellmigration and invasion ability by the AKT pathways. PTCSC1 may be an effective therapeutic target in bladder cancer.

Determination of the Expression of Latent Epstein Barr Virus in Omani Nasopharyngeal Carcinoma Patients

Background: Nasopharyngeal carcinoma(NPC) is a rare malignant carcinoma that develops in the epithelial lining of the nasopharyngeal mucosa It is the most common neoplasm of the Nasopharynxand it is associated with many risk factors; one of them is Epstein-Barr virus infection. An Epstein-Barr virus is a tumorigenic herpes virus that infects and persists in B-lymphocytes without causing disease. This virus is associated with significant pathological conditions, such as benign and malignant lymphoproliferation. Objectives: To determine Epstein -Barr encoded RNA 1&2 (EBER1,2) and latent membrane protein (LMP) expressionin formalin-fixed paraffin-embedded tissue samples obtained from Omani patients diagnosed with nasopharyngeal carcinoma.Also, to identify the pattern and the type(s) of cells infected with EBV in nasopharyngeal carcinoma tissue samples obtained from Omani patients. Moreover, to compare the sensitivity of Immuno histochemistry and in-situ Hybridization for the detection of EBV in the nasopharyngeal carcinoma tissue sample. Materials and Method:Thirteen formalin-fixed paraffin-embedded nasopharyngeal carcinoma tissue samples archived from the period 2010 to 2017, were obtained from the Pathology Departments of Sultan Qaboos University Hospital and the Armed Force Hospital. These tissue samples were processed using two different methods Immunohistochemistry (IHC) and In situ hybridization (ISH). Results:Eleven out of thirteen NPC Omani patients were positive for EBV (84.61%) by either LMP-IHC or EBER-ISH. All cells stained positive for EBV in NPC tissue samples was of malignant type rather than normal cell type. EBV is mostly detected in patients in the age group of less than 50 years old. Also out of the 13 NPC patients, seven females (58.34%), and six males (46.15%) were positive for EBV. Conclusion:This study may provide evidence indicating an association between EBV and nasopharyngeal carcinoma. In addition, the detection of EBV in NPC obtained from Omani patients may encourage the physician to consider using anti-herpes virus drugs in the treatment of EBV positive NPC patients as an additional tool for the treatment of this kind of malignancy.

Higher CD1a Levels Correlate with PD-L1 Expression and Predict Worse Overall Survival in Triple-Negative Breast Carcinoma

Objective: The aim of this study was to measure the expression of PD-L1, CD1a (a marker for immature dendritic cells), and CD83 (a marker for mature dendritic cells) and further examine the associations of PD-L1, CD83, and CD1a with overall survival (OS) in triple-negative breast carcinoma patients. Methods: PD-L1, CD1a, and CD83 expression in breast carcinoma tissues and CD83 expression in lymph node tissues were examined by immunohistochemistry and tissue microarray in 159 patients. Patients were classified into the low, medium, and high PD-L1, CD1a, and CD83 levels. Pearson χ2 test was used to analyze the correlations between PD-L1, CD1a, and CD83. The Kaplan-Meier method was used to calculate the OS. Multivariate analysis was used to identify determinants of 3- and 5-year OS. Results: 25.1, 25.8, and 49.1% of the patients had low, medium, and high PD-L1 levels, respectively. PD-L1 levels significantly correlated with CD1a (r = 0.30409, p < 0.001) and CD83 levels (r = 0.6146, p < 0.001) in breast carcinoma tissue, as well as CD83 levels (r = 0.17508, p = 0.027) in lymph node. The median OS was 83 months (range 12–106), and the 3- and 5-year OS rates were 94.97% (95% CI 91.57–98.37) and 86.79% (95% CI 81.53–92.06), respectively. Moreover, patients with high median CD1a levels had a significantly lower 5-year OS rate (75.6%) than those with low median CD1a levels (93.5%, p = 0.038). Conclusion: PD-L1, CD1a, and CD83 are variably expressed in triple-negative breast carcinoma tissues, and PD-L1 expression correlates with CD1a and CD83. Higher CD1a levels correlate with PD-L1 expression and predict worse OS in triple-negative breast carcinoma.